Biotech’s Q2 Numbers Paint a Picture of the Good, the Bad and the Ugly

Copy of Copy of Copy of Copy of Copy of Copy of Copy of Copy of Copy of Copy of Copy of Copy of Copy of Copy of Copy of Copy of Copy of This Pharma Company Is Betting Big On A Chinese Ozempic Riva

Biotech dealmaking remains strong in 2025, fueled by licensing, M&A, and a surge in AI-driven agreements. The article features several DealForma charts that break down these trends across healthcare, therapeutics, and medtech. Read it here

DealForma Research

Explore More
Biopharma Therapeutics and Platforms M&A - 2025 Review

Biopharma Therapeutics and Platforms M&A – 2025 Review

Biopharma Therapeutics and Platforms R&D Partnerships - 2025 Review

Biopharma Therapeutics and Platforms R&D Partnerships – 2025 Review

Dermatology M&A - 2024-2025 Review

Dermatology M&A – 2024-2025 Review

All of this by stage, disease indication, modality, target…

Schedule your Demo
+ 0 k
Licensing Deals
+ 0 k
M&A
+ 0 k
Other Deals
+ 0 k
Funding Rounds
+ 0 k
Company Profiles
+ 0 k
Drug Sales Figures
DealForma Logo

DealForma is the biopharma deal database providing you comprehensive information and dedicated analyst support to help you be more confident using quality data in your business development research.

Linkedin

Database

Company

Comparisons

Website Design by Once Interactive